Table 2. Emerging therapies for the treatment of musculoskeletal consequences of androgen deprivation therapy.
Agents targeting bone | Agents targeting muscle |
---|---|
Chloride Channel Modulators | Androgen Receptor Modulators (SARM) |
Anti-cathepsin K | GH Secretagogues |
Anti-Integrins | PPAR-beta Modulators |
Src inhibitors | Anti-Myostatin Antibodies |
Androgen Receptor Modulators (SARM) | Myostatin Soluble Receptors |
GLP2 | Anti-Activin II Receptors |
Inhibitor of gut serotonin | Angiotensin II Blockades |
Anti-sclerostin | Beta-2 Receptor Agonists |
Anti-Dickkopf | Anti-IL-6 |
Modulators of LRPs Pathway | |
Anti-activin | Anti-activin |